今天早上 1000 * $0.41

计划拿到下周

[非投资建议，清零风险很大]

pink list or over the counter?

洪荒之前 写了： ↑18 7月 2025, 13:52

pink list or over the counter?

Robinhood 上有，没说是啥。
Update: Grok "IXHL is a Pink Sheet stock, traded over the counter."

https://robinhood.com/stocks/IXHL

Margin Maintenance ratio: 100%

Just sold 1000 at $0.64

spring 写了： ↑18 7月 2025, 13:57

洪荒之前 写了： ↑18 7月 2025, 13:52

pink list or over the counter?

Robinhood 上有，没说是啥。
Update: Grok "IXHL is a Pink Sheet stock, traded over the counter."

https://robinhood.com/stocks/IXHL

Margin Maintenance ratio: 100%

Just sold 1000 at $0.64

一个月前的新闻：

https://ir.incannex.com/news-releases/n ... sa-phase-2

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
June 18, 2025

Top-line results expected July 2025 as development of first-in-class OSA drug advances

Joel Latham, President and CEO of Incannex, commented, "Achieving database lock on schedule demonstrates our strong clinical capabilities and commitment to advancing a much-needed therapy for obstructive sleep apnoea. IHL-42X represents a breakthrough opportunity to address a condition affecting hundreds of millions of people globally, with no approved oral pharmacological treatment available. We are excited by what lies ahead."

现在还没有新闻，下周会有更新？如果效果不好，股价要疯狂跳水了

再来一个
SYTA

最近一个月

前半个月暴涨，均线发散，后半个月横盘，均线收敛。很快会再次发散？

Grok. Siyata Mobile Inc. (SYTA)

• Price: Under $5 (as of recent data).
• Float: Approximately 4.8 million shares post-reverse split.
• Volume: Known for spikes in trading volume, with a notable multi-day run in May 2025 driven by high volume and AI-related catalysts.
• Why It Could Move: SYTA has shown explosive potential, with an 810% surge in May 2025 tied to its AI narrative and merger with Core Gaming, which is presenting at the Maxim Group’s 2025 Virtual Tech Conference. Low float combined with viral growth and AI-driven news could reignite interest, especially if volume spikes again. The stock’s history of “supernova” chart patterns suggests it could see sharp moves if momentum returns.
• Risks: Highly volatile, not a buy-and-hold stock, and prone to rapid drops due to low float and speculative trading.

ABCL
最近一个月

Grok. AbCellera Biologics (ABCL)

• Price: Under $5 (as of June 2025 data).
• Float: Not explicitly stated, but penny stocks on major exchanges like Nasdaq often have relatively low floats compared to larger caps.
• Volume: Minimum 30-day average daily volume of 200,000 shares, with recent activity showing bullish patterns.
• Why It Could Move: ABCL recently triggered a double bottom bullish reversal after hitting a $1.89 low, reclaiming its 20-week and 50-week moving averages. Its biotech focus and listing on Nasdaq provide some regulatory oversight, reducing certain risks associated with OTC penny stocks. The stock’s technical setup and positive one-month performance in June 2025 suggest potential for further gains if bullish patterns continue.
• Risks: Biotech penny stocks are speculative, and price patterns may take longer to unfold, with potential for larger drawdowns.

HIT

Health In Tech, Inc. (HIT) Evaluation

Overview: Health In Tech (Nasdaq: HIT) is an insurtech platform using AI to streamline healthcare processes for small/medium businesses, offering reference-based pricing, group captives, and a SaaS quoting platform.

Key Data (July 2025):

• Price: ~$0.83
• Float: Likely low (market cap ~$45.23M)
• Volume: High, often exceeding 200,000 shares daily
• Market Cap: ~$45.23M

Financials:

• Revenue: $19.49M (2024), up 1.77%; Q1 2025 up 56% to $8.0M
• Net Income: $670,477 (2024), down 72.93%
• P/E Ratio: 11.98

Performance:

• Recent: 82% drop in March 2025 after Medicare/Medicaid fraud concerns; regulatory fears persist
• Trend: Down 85.5% over six months, -70.92% below 200-day moving average
• Analyst Outlook: “Strong Buy” with $2.50 target (₂₀₀% upside)

Catalysts:

• Strong Q1 2025 revenue growth
• AI-driven platform and new executive hires
• Risks: Regulatory uncertainty, weak earnings

Assessment: HIT fits high-volume, low-float penny stock criteria with speculative upside due to AI focus and growth potential. However, regulatory risks and an 82% drop signal high volatility. Suitable for aggressive traders; verify real-time data and allocate minimally.

原来是小药股啊。

以前玩过几个医械股，比如CAMH，不知还在不在了，就是赌FDA Phase III Approval.